Inmunoterapia en 1L del CPCNP: monoterapia y/o tratamiento combinado - page 22

1L NSCLC: Keynote 021

Langer CJ, et al. Lancet Oncol 2016; Soria JC, et al. ESMO 2016

OS 12 m 75% vs 73%

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,12,13,14,15,16,17,18,19,20,21 23,24,25,26,27,28,29,30,31,32,...42